newswire, breaking biotechnology and pharma news

Wednesday, April 17, 2013

Penny Stocks; Aethlon Medical (OTCBB: AEMD) Moves Following News on Contract

Point Roberts, WA - April 17, 2013 ( newswire) -, an investor research portal specializing in sector research for independent investors including biodefense and homeland security stocks issues a trading alert for Aethlon Medical, Inc. (OTCBB: AEMD), trading at $0.1099, up 0.0070 6.80% 12:43PM EDT on over 688,000 shares. The stock had a morning high of $0.12.

The company reported yesterday it entered into a subcontract agreement with Battelle Memorial Institute (Battelle) to provide services underlying a $22.8 million prime contract that was recently awarded to Battelle by the Defense Advanced Research Projects Agency (DARPA).
According to the press release, "The objective of this contract program is to integrate component technologies developed in DARPA's Dialysis Like Therapeutics (DLT) program into medical device that would save military and civilian lives by effectively treating sepsis. Beyond expanding our opportunity in the DLT program, we are honored to have the opportunity to work with Battelle (the world's largest independent research and development organization) on this endeavor."
The Company's Chairman and CEO also went on to say, "I am pleased to report that the funding spigot for countermeasures against bioterror and pandemic threats has been turned back on. Last month, The Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2013 was signed into law by President Obama. The law reauthorizes provisions of the Project Bioshield Act of 2004 and extends the mandate of the Biomedical Advanced Research and Development Authority (BARDA) to support medical countermeasure development for biothreat agents for possible inclusion in the U.S. Strategic National Stockpile. PAHPRA also enhances the authority of the FDA to support rapid responses to public health emergencies by clarifying that even before an event occurs, FDA may issue an emergency use authorization to allow emergency use of certain products as medical countermeasures. The Congressional Budget Office estimates that $11 billion will be spent on PAHPRA between fiscal years 2014 to 2018."
Full news: Newswire More info on AEMD:
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit
About is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow on Twitter!/Investorideas
Follow on Facebook
Follow News on at
Sign up for the free news and stock alerts including biotech and biodefense stocks
Become an Member and access our 14 online stock directories 24/7 - biotech and life sciences, biodefense and homeland security , water, renewable energy, mining stocks
Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: AEMD is a paid client for news release and content distribution on the newswire and syndication partners (annual fee program 9700)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source -

No comments:

Post a Comment